SCHEMBL12848878

SCHEMBL12848878

COc1cc(-c2cn3cccnc3n2)ccc1OCc1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.62
ALDH1A1 P00352 11/20 0.62
HPGD P15428 7/20 0.62
SMN1; SMN2 Q16637 6/20 0.62
MAPT P10636 6/20 0.62
RAB9A P51151 5/20 0.62
GLA P06280 4/20 0.62
GAA P10253 4/20 0.62
NPC1 O15118 4/20 0.62
TP53 P04637 5/20 0.60
THRB P10828 2/20 0.55
POLB P06746 3/20 0.54
HSD17B10 Q99714 4/20 0.53
CYP1A2 P05177 1/20 0.53
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
LMNA P02545 2/20 0.52
RECQL P46063 1/20 0.51
TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6520519 0.91 KDM4E (0.65) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL12797313 0.89 ALDH1A1 (0.64) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL10809568 0.84 KDM4E (0.79) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL12848792 0.84 PPARG (0.62) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL6527793 0.84 RAB9A (0.68) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL12848981 0.83 HRH3 (0.62) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL12848910 0.82 PPARG (0.54) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL12848931 0.82 PPARG (0.61) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL23407644 0.81 KDM4E (0.74) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL29620769 0.81 KDM4E (0.74) KDM4EALDH1A1HPGDSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895599-B2 Lipoprotein lipase-activating compositions comprising benzene derivates OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2014-11-25 US disclosed
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2013-11-07 US disclosed
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES LPL, LIPC, LIPE KDM4E 1225/4885ALDH1A1 332/4885HPGD 1821/4885
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES LPL, LIPC, LIPE KDM4E 1378/4885ALDH1A1 419/4885HPGD 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.